

SUPPLEMENTAL DATA**Supplemental Figure Legend**

Figure S1. LC3B staining with brown chromogen in normal tissues from YTMA96 as follows: (a) normal brain tissue; (b) normal renal tubular epithelium; (c) an area in close proximity to ovarian carcinoma containing an LC3B-positive infiltrating macrophage ($m\phi$) along with LC3B-negative lymphocytes (L); (d) breast carcinoma-infiltrating macrophage ($m\phi$); (e) breast carcinoma-associated stromal fibroblasts; (f) melanoma-associated stromal fibroblasts abutting a primary invasive melanoma. Arrows denote LC3B punctate staining.

Table S1: Multitumor microarray YTMA96--LC3B staining intensity.

	LC3B % moderate-strong staining (Mean \pm SD)	n =
Astrocytoma	97 \pm 7	11
Hepatocellular carcinoma	96 \pm 5	18
Lymphoma non-Hodgkins	95 \pm 10	10
Prostate carcinoma	95 \pm 11	19
Gastric carcinoma	93 \pm 6	14
Glioblastoma	93 \pm 5	11
Ovarian carcinoma	93 \pm 7	14
Thyroid papillary carcinoma	89 \pm 11	12
Lung carcinoma	87 \pm 13	18
Malignant melanoma	86 \pm 18	20
Endometrial carcinoma	85 \pm 13	13
Bladder carcinoma	84 \pm 11	20
Colon carcinoma	83 \pm 8	14
Sarcoma	80 \pm 11	16
Squamous cell carcinoma	80 \pm 7	15
Pancreatic carcinoma	76 \pm 19	11
Breast carcinoma	72 \pm 13	20
Lymphoma Hodgkins	68 \pm 24	10
Renal cell carcinoma	63 \pm 34	12
Testis germ cell carcinoma	60 \pm 12	14

Results represent the mean \pm SD of the percentage of tumors with moderate to strong staining intensities on multitumor microarray YTMA96. Tumors were scored on a 0-3⁺ scale with 0/1+ = none to weak (not shown) and 2+/3+ = moderate to strong (shown above). Two slides of YTMA96 were stained with anti-LC3B using a brown chromogen. Both slides were scored independently by two observers and the were data combined such that the means represent a total of 4 data sets.

Table S2: Breast cancer array YTMA49--Clinicopathologic criteria vs LC3B staining intensity (AQUA score).

	n	LC3B mean \pm std	p =
Histologic Grade			0.2034
1	10	20.9 \pm 7.4	
2	167	34.8 \pm 25.9	
3	117	32.7 \pm 23.5	
Nuclear Grade			< 0.0001
1	95	17.9 \pm 12.2	
2	292	24.8 \pm 18.4	
3	156	40.0 \pm 30.1	
Tumor Size			= 0.0117
< 2 cm	187	23.4 \pm 18.3	
2-5 cm	259	28.9 \pm 24.3	
\geq 5 cm	88	31.1 \pm 27.8	
Positive Nodes			< 0.0001
0 (node neg.)	286	21.2 \pm 18.5	
1-3	139	37.0 \pm 27.9	
4-9	92	30.4 \pm 23.0	
\geq 10	60	29.7 \pm 17.2	
Patient Age			< 0.0001
< 50 years	170	37.9 \pm 46.4	
\geq 50	425	26.8 \pm 20.9	
Estrogen Receptor			= 0.0009
Negative	261	30.9 \pm 26.2	
Positive	326	24.6 \pm 18.9	
Prog. Receptor			= 0.0043
Negative	267	30.3 \pm 24.5	
Positive	320	24.9 \pm 20.6	
HER2/neu			= 0.2943
0	341	26.7 \pm 21.7	
1	113	28.7 \pm 24.7	
2	41	29.4 \pm 25.7	
3	61	32.5 \pm 22.9	

Table S3: Breast cancer array YTMA49--Clinicopathologic criteria vs relative risk (univariate survival statistics).

	Rel Risk	95% C.I.	p =
Histologic Grade			5142
1	1.00		
2	1.15	(0.505-2.632)	
3	1.36	(0.589-3.118)	
Nuclear Grade			p = 0.0064
1	1.00		
2	1.10	(0.789-1.540)	
3	1.64	(1.149-2.338)	
Tumor Size			p < 0.0001
< 2 cm	1.00		
2-5 cm	1.73	(1.287-2.332)	
≥ 5 cm	2.93	(2.082-4.134)	
Positive Nodes			p < 0.0001
0 (node neg)	1.00		
1-3	1.96	(1.460-2.633)	
4-9	2.37	(1.705-3.300)	
≥10	3.22	(2.243-4.055)	
Patient Age			p < 0.1215
< 50 years	1.00		
≥ 50	1.24	(0.945-1.619)	
Estrogen Receptor			p = 0.0032
Positive	1.00		
Negative	1.43	(1.126-1.805)	
Prog. Receptor			p = 0.0013
Positive	1.00		
Negative	1.47	(1.163-1.863)	
HER2/neu			p = 0.4339
0	1.00		
1	0.98	(0.719-1.345)	
2	1.17	(0.732-1.857)	
3	1.19	(0.794-1.714)	

Table S4: Melanoma microarray YTMA20--Clinicopathologic criteria vs LC3B staining intensity (AQUA score).

Primary tumors (invasive)			
	n	LC3B mean \pm std	p =
Breslow Depth			0.0479
\leq 1mm	58	23.0 \pm 13.8	
1 – 2 mm	48	21.0 \pm 13.6	
2 – 4 mm	58	21.6 \pm 18.7	
$>$ 4 mm	44	32.6 \pm 24.1	
Clark Level			0.1066
II	24	18.3 \pm 13.5	
III	70	21.2 \pm 14.2	
IV	84	24.0 \pm 17.4	
V	26	33.4 \pm 28.9	
TILs			0.6681
Absent	10	19.8 \pm 10.9	
Sparse	25	22.0 \pm 19.3	
NonBrisk	65	25.9 \pm 20.2	
Brisk	29	23.1 \pm 16.1	
Ulceration			0.1094
Absent	81	27.5 \pm 14.9	
Present	49	22.1 \pm 23.0	
Sex			0.1973
Male	71	23.1 \pm 15.3	
Female	61	23.8 \pm 19.8	
Age			0.0375
$<$ 60	65	27.4 \pm 21.4	
\geq 60	67	20.7 \pm 14.2	
Metastatic tumors			
Location	n	LC3B mean \pm std	p = 0.4092
Lymph Node	86	38.6 \pm 36.9	
Skin	43	30.6 \pm 24.8	
Distant	32	33.4 \pm 31.4	

Table S5: Multitumor array YTMA96--Mitotic figures vs LC3B staining intensity.

	LC3B expression		p-value
	0/1+	2+/3+	
Mitotic figures observed	2	89	p < 0.002
Mitotic figures expected	15	76	

Mitotic figures were counted in two slides of multitumor array YTMA96 stained for LC3B. The expected number of mitotic figures was based on a random distribution between LC3B low- and high-staining tumors comprising 16% and 84% of the total respectively (Table S5). The p-value was calculated through Pearson's chi-squared test with Yates' continuity correction.

Lazova et al. CCR revision-1
Punctate LC3B..

Figs 1-6

Supplemental Fig S1

Fig S1

